BEERSE, Belgium--(BUSINESS WIRE)--Janssen-Cilag International NV (Janssen) today announced the preliminary results from the Phase IIa OSIRIS trial, at the Liver Meeting®, the Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco. The OSIRIS trial, investigating once daily OLYSIO® (simeprevir) in combination with sofosbuvir in hepatitis C virus (HCV) genotype 4 infected patients, with and without liver cirrhosis, demonstrated treatment to be safe and ......
↧